Table 2 Pre-existing Comorbidities
From: Circulating calprotectin levels four months after severe and non-severe COVID-19
|  | Bern Non-ICU (n = 99) | Bern Post-ICU (n = 25) | Lausanne Post-ICU (n = 68) |
|---|---|---|---|
Asthma | 14 (14.1%) | 1 (4.0%) | 10 (14.9%) |
ILD | 1 (1.0%) | 2 (8.0%) | 0 (0.0%) |
COPD | 0 (0.0%) | 0 (0.0%) | 2 (3.0%) |
Cor. Art. Disease | 5 (5.1%) | 2 (8.0%) | 3 (4.5%) |
Art. Hypertension | 10 (10.2%) | 11 (44.0%) | 32 (47.8%) |
Heart failure | 1 (1.0%) | 2 (8.3%) | 5 (7.5%) |
Pulm. Embolism | 1 (1.0%) | 3 (12.0%) | 1 (1.5%) |